Transport mechanism of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors at the blood-brain barrier - PubMed (original) (raw)
. 1993 Dec;267(3):1085-90.
Affiliations
- PMID: 8263769
Transport mechanism of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors at the blood-brain barrier
A Tsuji et al. J Pharmacol Exp Ther. 1993 Dec.
Abstract
The transport mechanism of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors through the blood-brain barrier was studied in vitro by using primary cultures of bovine brain capillary endothelial cells (BCEC). The uptake of HMG-CoA reductase inhibitors with the lactone form, [14C]lovastatin and [14C]simvastatin, was slightly decreased to 65% of the control uptake (37 degrees C) at low temperature (4 degrees C) and was not affected by pretreatment of the BCEC with metabolic inhibitors (2,4-dinitrophenol and rotenone). [14C]Simvastatin acid (the lactone ring-opened form) was taken up in a markedly temperature- and concentration-dependent fashion, whereas the uptake of [14C] pravastatin was negligible. At pH below 7.4, the uptake rate of [14C]simvastatin acid by the BCEC increased markedly with decreasing medium pH, whereas almost pH-independent uptake was observed in the presence of 1 mM simvastatin acid. Additional studies using an in situ rat brain perfusion method showed that the in vivo cerebrovascular permeation of [14C]simvastatin acid in rats was significantly inhibited in the presence of 1 mM simvastatin acid, demonstrating that the transport system for the acid forms of HMG-CoA reductase inhibitors functions under in vivo conditions. Several monocarboxylic acids significantly inhibited the uptake of [14C]simvastatin acid by the BCEC, whereas dicarboxylic acids did not. The uptake of [14C]simvastatin acid by the BCEC was competitively inhibited by 15 mM acetic acid. Accordingly, we concluded that HMG-CoA reductase inhibitors in lactone form are transported via simple diffusion, whereas those having an acid form are transported across the blood-brain barrier via a carrier-mediated transport mechanism for monocarboxylic acids.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
- Transport of monocarboxylic acids at the blood-brain barrier: studies with monolayers of primary cultured bovine brain capillary endothelial cells.
Terasaki T, Takakuwa S, Moritani S, Tsuji A. Terasaki T, et al. J Pharmacol Exp Ther. 1991 Sep;258(3):932-7. J Pharmacol Exp Ther. 1991. PMID: 1890627 - In vivo and in vitro blood-brain barrier transport of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors.
Saheki A, Terasaki T, Tamai I, Tsuji A. Saheki A, et al. Pharm Res. 1994 Feb;11(2):305-11. doi: 10.1023/a:1018975928974. Pharm Res. 1994. PMID: 8165193 - Inhibition of rat brain prostaglandin D synthase by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
Islam F, Watanabe Y, Hayaishi O. Islam F, et al. Biochem Int. 1990 Nov;22(4):601-5. Biochem Int. 1990. PMID: 2127671 - Analysis of five HMG-CoA reductase inhibitors-- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies.
Pasha MK, Muzeeb S, Basha SJ, Shashikumar D, Mullangi R, Srinivas NR. Pasha MK, et al. Biomed Chromatogr. 2006 Mar;20(3):282-93. doi: 10.1002/bmc.561. Biomed Chromatogr. 2006. PMID: 16143964 Review. - Brain iron homeostasis.
Moos T. Moos T. Dan Med Bull. 2002 Nov;49(4):279-301. Dan Med Bull. 2002. PMID: 12553165 Review.
Cited by
- Neuroprotective Effects of Low-Dose Statins in the Retinal Ultrastructure of Hypercholesterolemic Rabbits.
Fernández-Navarro J, Aldea P, de Hoz R, Salazar JJ, Ramírez AI, Rojas B, Gallego BI, Triviño A, Tejerina T, Ramírez JM. Fernández-Navarro J, et al. PLoS One. 2016 May 4;11(5):e0154800. doi: 10.1371/journal.pone.0154800. eCollection 2016. PLoS One. 2016. PMID: 27144842 Free PMC article. - Cholesterol level and statin use in Alzheimer disease: II. Review of human trials and recommendations.
Shepardson NE, Shankar GM, Selkoe DJ. Shepardson NE, et al. Arch Neurol. 2011 Nov;68(11):1385-92. doi: 10.1001/archneurol.2011.242. Arch Neurol. 2011. PMID: 22084122 Free PMC article. Review. - Cellular uptake of fluvastatin, an inhibitor of HMG-CoA reductase, by rat cultured hepatocytes and human aortic endothelial cells.
Ohtawa M, Masuda N, Akasaka I, Nakashima A, Ochiai K, Moriyasu M. Ohtawa M, et al. Br J Clin Pharmacol. 1999 Apr;47(4):383-9. doi: 10.1046/j.1365-2125.1999.00901.x. Br J Clin Pharmacol. 1999. PMID: 10233202 Free PMC article. - Transporters at CNS barrier sites: obstacles or opportunities for drug delivery?
Sanchez-Covarrubias L, Slosky LM, Thompson BJ, Davis TP, Ronaldson PT. Sanchez-Covarrubias L, et al. Curr Pharm Des. 2014;20(10):1422-49. doi: 10.2174/13816128113199990463. Curr Pharm Des. 2014. PMID: 23789948 Free PMC article. Review. - Monocarboxylate transporter (MCT) mediates the transport of gamma-hydroxybutyrate in human kidney HK-2 cells.
Wang Q, Lu Y, Morris ME. Wang Q, et al. Pharm Res. 2007 Jun;24(6):1067-78. doi: 10.1007/s11095-006-9228-6. Epub 2007 Mar 22. Pharm Res. 2007. PMID: 17377745
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical